Pharmaceutical composition with improved bioavailability
The invention relates to solid dispersions of poorly water soluble compounds, in particular 4-{[(2R, 3S, 4R, 5S)-4-(4-chloro-2-Fluorophenyl)-3-(3-chloro-2-Fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-pyrrolidine-2-carbonyl]amino}-3- Methoxy-Benzoic Acid, formed by solvent co-precipitation or spray d...
Saved in:
| Main Authors | , , , , , |
|---|---|
| Format | Patent |
| Language | Chinese English |
| Published |
12.02.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The invention relates to solid dispersions of poorly water soluble compounds, in particular 4-{[(2R, 3S, 4R, 5S)-4-(4-chloro-2-Fluorophenyl)-3-(3-chloro-2-Fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-pyrrolidine-2-carbonyl]amino}-3- Methoxy-Benzoic Acid, formed by solvent co-precipitation or spray drying, resulting in improved bioavailability, safety and tolerability of said compounds.
本发明涉及通过溶剂共沉淀或喷雾干燥形成的水难溶性化合物，特别是4-{[(2R,3S,4R,5S)-4-(4-氯-2-氟苯基)-3-(3-氯-2-氟苯基)-4-氰基-5-(2,2-二甲基丙基)-吡咯烷-2-羰基]氨基}-3-甲氧基-苯甲酸的固体分散体，其导致所述化合物的改善的生物利用度、安全性和耐受性。 |
|---|---|
| AbstractList | The invention relates to solid dispersions of poorly water soluble compounds, in particular 4-{[(2R, 3S, 4R, 5S)-4-(4-chloro-2-Fluorophenyl)-3-(3-chloro-2-Fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-pyrrolidine-2-carbonyl]amino}-3- Methoxy-Benzoic Acid, formed by solvent co-precipitation or spray drying, resulting in improved bioavailability, safety and tolerability of said compounds.
本发明涉及通过溶剂共沉淀或喷雾干燥形成的水难溶性化合物，特别是4-{[(2R,3S,4R,5S)-4-(4-氯-2-氟苯基)-3-(3-氯-2-氟苯基)-4-氰基-5-(2,2-二甲基丙基)-吡咯烷-2-羰基]氨基}-3-甲氧基-苯甲酸的固体分散体，其导致所述化合物的改善的生物利用度、安全性和耐受性。 |
| Author | MA HUA ZHANG YU-E SANDHU HARPREET K SHAH NAVNIT HARGOVINDAS LOMUSCIO STEVE MATCHETT MICHAEL ALLEN |
| Author_xml | – fullname: SHAH NAVNIT HARGOVINDAS – fullname: MA HUA – fullname: ZHANG YU-E – fullname: LOMUSCIO STEVE – fullname: MATCHETT MICHAEL ALLEN – fullname: SANDHU HARPREET K |
| BookMark | eNrjYmDJy89L5WSwCMhILMpNTE4tLclMTsxRSM7PLcgvzizJzM9TKM8syVDIzC0oyi9LTVFIysxPLEvMzElMyszJLKnkYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQVAI_NSS-Kd_QwNjYxNjc3NjByNiVEDAIFOMQc |
| ContentType | Patent |
| DBID | EVB |
| DatabaseName | esp@cenet |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Sciences |
| DocumentTitleAlternate | 具有改善的生物利用度的药物组合物 |
| ExternalDocumentID | CN112353762A |
| GroupedDBID | EVB |
| ID | FETCH-epo_espacenet_CN112353762A3 |
| IEDL.DBID | EVB |
| IngestDate | Fri Jul 19 12:56:25 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | Chinese English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-epo_espacenet_CN112353762A3 |
| Notes | Application Number: CN202011052449 |
| OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210212&DB=EPODOC&CC=CN&NR=112353762A |
| ParticipantIDs | epo_espacenet_CN112353762A |
| PublicationCentury | 2000 |
| PublicationDate | 20210212 |
| PublicationDateYYYYMMDD | 2021-02-12 |
| PublicationDate_xml | – month: 02 year: 2021 text: 20210212 day: 12 |
| PublicationDecade | 2020 |
| PublicationYear | 2021 |
| RelatedCompanies | F.HOFFMANN-LA ROCHE AG |
| RelatedCompanies_xml | – name: F.HOFFMANN-LA ROCHE AG |
| Score | 3.4260595 |
| Snippet | The invention relates to solid dispersions of poorly water soluble compounds, in particular 4-{[(2R, 3S, 4R,... |
| SourceID | epo |
| SourceType | Open Access Repository |
| SubjectTerms | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| Title | Pharmaceutical composition with improved bioavailability |
| URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210212&DB=EPODOC&locale=&CC=CN&NR=112353762A |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQsbRIMbdIMkzVTU1LNdU1SbEEZimjNGNdYDloZmEIjHMT8HFNvn5mHqEmXhGmEUwMWbC9MOBzQsvBhyMCc1QyML-XgMvrAsQglgt4bWWxflImUCjf3i3E1kUN2jsG9V8MjdRcnGxdA_xd_J3VnJ1tnf3U_IJsDUF7QoGZyciRmYEV1IwGnbPvGuYE2pVSgFyluAkysAUATcsrEWJgqsoQZuB0ht28JszA4Qud8AYyoXmvWITBIiADefhZAbQYHLriSgE0mqqQCR4fSE1RSMrMTywDOh5yBHelKIOim2uIs4cu0AnxcP_GO_shXGssxsCSl5-XKsGgYJ6SBqz8U5ONzVMMTUyNDJLSTE3NUoxTDIxS0lJT0ywkGaRwmyOFT1KagQsUdrrge05kGFhKikpTZYF1bUmSHDiQAOaig8A |
| link.rule.ids | 230,309,786,891,25594,76906 |
| linkProvider | European Patent Office |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQsbRIMbdIMkzVTU1LNdU1SbEEZimjNGNdYDloZmEIjHMT8HFNvn5mHqEmXhGmEUwMWbC9MOBzQsvBhyMCc1QyML-XgMvrAsQglgt4bWWxflImUCjf3i3E1kUN2jsG9V8MjdRcnGxdA_xd_J3VnJ1tnf3U_IJsDUF7QoGZyciRmYHVHHQ6L6jpFOYE2pVSgFyluAkysAUATcsrEWJgqsoQZuB0ht28JszA4Qud8AYyoXmvWITBIiADefhZAbQYHLriSgE0mqqQCR4fSE1RSMrMTywDOh5yBHelKIOim2uIs4cu0AnxcP_GO_shXGssxsCSl5-XKsGgYJ6SBqz8U5ONzVMMTUyNDJLSTE3NUoxTDIxS0lJT0ywkGaRwmyOFT1KegdMjxNcn3sfTz1uagQsUjrrgO09kGFhKikpTZYH1bkmSHDjAADjXhq0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Pharmaceutical+composition+with+improved+bioavailability&rft.inventor=SHAH+NAVNIT+HARGOVINDAS&rft.inventor=MA+HUA&rft.inventor=ZHANG+YU-E&rft.inventor=LOMUSCIO+STEVE&rft.inventor=MATCHETT+MICHAEL+ALLEN&rft.inventor=SANDHU+HARPREET+K&rft.date=2021-02-12&rft.externalDBID=A&rft.externalDocID=CN112353762A |